Andrew Martin

Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).

orcid ID: 0000-0001-5804-2295

Scopus Author ID: 57223730436

Grants

Category 1: $14.3M Category 3: $131.8M

Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.

Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).